FDA Clearance Tracker · P150035-S042
AVEIR VR Real-World Evidence Study
Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Oct 21, 2026
Approved
Time to decision
26 days
Received Sep 25, 2026. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P150035-S042
- Device name
- AVEIR VR Real-World Evidence Study
- Applicant
- ABBOTT MEDICAL
- Applicant location
- Sylmar, CA
- Received
- Sep 25, 2026
- Decided
- Oct 21, 2026
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P150035
Device type
- Device type
- Leadless pacemaker (PNJ)
- Device class
- Class III
- Regulation
- 21 CFR 870.3610
- Specialty
- CardiologyElectrophysiology
FDA's approval statement
As written in FDA's record.
approval of the revised protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P150035/S041.
Source documents
Other decisions for ABBOTT MEDICAL
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P260019 · Decided Oct 27, 2026 · 180 days after receipt
Device type: Para-device leak occluder (SJT) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.